Loading...
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT and FLT3 in hematologic malignancies: Mutant KIT and FLT3 response to Tyrosine Kinase Inhibitors
Mutations in two type-3 receptor tyrosine kinases (RTK), KIT and FLT3, are common in both acute myeloid leukemia (AML) and systemic mastocytosis (SM) and lead to hyperactivation of key signaling pathways. Fortunately, a significant number of tyrosine kinase inhibitors TKIs have been developed that t...
Na minha lista:
| Udgivet i: | Br J Haematol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7887860/ https://ncbi.nlm.nih.gov/pubmed/31309543 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16092 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|